Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Aug;18(8):626-630.
doi: 10.1089/bfm.2023.0102.

Monoclonal Antibody Therapy of Breastfeeding Patient Infected with SARS-CoV-2: A Case Report

Nicole E Marshall  1 , Madison B Blanton  2   3 , Brianna M Doratt  2 , Delphine C Malherbe  2 , Monica Rincon  1 , Ilhem Messaoudi  2
Affiliations
Case Reports

Monoclonal Antibody Therapy of Breastfeeding Patient Infected with SARS-CoV-2: A Case Report

Nicole E Marshall et al. Breastfeed Med. 2023 Aug.

Abstract

Introduction: Although safety data demonstrated the efficacy and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination for all individuals over 6 months of age, including pregnant and breastfeeding individuals, optimal treatment courses for symptomatic pregnant and lactating individuals infected with SARS-CoV-2 remain to be defined. Case Description: A coronavirus disease 2019 (COVID-19)-vaccinated breastfeeding woman received anti-SARS-CoV-2 monoclonal antibody treatment casirivimab-imdevimab 5 days after diagnosis of a symptomatic breakthrough SARS-CoV-2 infection. Results and Conclusions: The patient did not present with obvious defects in innate or adaptive cellular subsets, but compared with controls had minimal maternal antibody response to recommended pregnancy vaccinations including SARS-CoV-2 and tetanus, diphtheria, pertussis (TDaP). The outcome of the monoclonal antibody infusion treatment was favorable as it transiently increased SARS-CoV-2 antibody titers in plasma and human milk compartments.

Keywords: SARS-CoV-2 infection; immune response; lactation; monoclonal antibody therapy.

PubMed Disclaimer

Conflict of interest statement

No competing financial interests exist.

Similar articles

See all similar articles

References

    1. Rubin R. Pregnant people's paradox-excluded from vaccine trials despite having a higher risk of COVID-19 complications. JAMA 2021;325(11):1027–1028; doi: 10.1001/jama.2021.2264 - DOI - PubMed
    1. Kons KM, Wood ML, Peck LC, et al. . Exclusion of reproductive-aged women in COVID-19 vaccination and clinical trials. Womens Health Issues 2022;32(6):557–563; doi: 10.1016/j.whi.2022.06.004 - DOI - PMC - PubMed
    1. Safadi MAP, Spinardi J, Swerdlow D, et al. . COVID-19 disease and vaccination in pregnant and lactating women. Am J Reprod Immunol 2022;88(1):e13550; doi: 10.1111/aji.13550 - DOI - PMC - PubMed
    1. Goldshtein I, Steinberg DM, Kuint J, et al. . Association of BNT162b2 COVID-19 vaccination during pregnancy with neonatal and early infant outcomes. JAMA Pediatr 2022;176(5):470–477; doi: 10.1001/jamapediatrics.2022.0001 - DOI - PMC - PubMed
    1. De Paris K, Permar SR. Routine SARS-CoV-2 vaccination for all children. Immunol Rev 2022;309(1):90–96; doi: 10.1111/imr.13108 - DOI - PMC - PubMed

Publication types

LinkOut - more resources

-